Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Sci ; 111(6): 1543-1555, 2022 06.
Article in English | MEDLINE | ID: mdl-35041831

ABSTRACT

Members of the IQ Consortium ″Working Group on Characterization on Amorphous Solid Dispersions″ shares here a perspective on the analytical challenges, and limitations of detecting low levels of crystalline drug substance in amorphous solid dispersions (ASDs) and associated drug products. These companies aim to employ highly sensitive commercially available analytical technologies to guide development, support control strategies, and enable registration of quality products. We hope to promote consistency in development and registration approaches and guide the industry in development of "characterization best practices" in the interest of providing high quality products for patients. The first half of this perspective highlights the unique challenges of analytical methodologies to monitor crystalline drug substance in ASDs and their associated drug products. Challenges around use of limit tests, analyte spiking experiments, and method robustness are also underscored. The latter half describes the merits and limitations of the diverse analytical "toolbox" (such as XRPD, NIR and DSC), which can be readily applied during development and, in some cases, considered for potential application and validation in the commercial QC setting when necessary.


Subject(s)
Chemistry, Pharmaceutical , Calorimetry, Differential Scanning , Chemistry, Pharmaceutical/methods , Crystallization/methods , Humans , Solubility , X-Ray Diffraction
2.
Mol Pharm ; 17(12): 4564-4571, 2020 12 07.
Article in English | MEDLINE | ID: mdl-33151697

ABSTRACT

Seeded growth rates of ritonavir in copovidone at 75% relative humidity (RH) and 50 °C were evaluated by single-particle tracking second harmonic generation (SHG) microscopy and found to be ∼3-fold slower for crystallites at the surface compared to the bulk. The shelf lives of final dosage forms containing amorphous solid dispersions (ASDs) are often dictated by the rates of active pharmaceutical ingredient crystallization. Upon exposure to elevated RH, the higher anticipated water content near the surfaces of ASDs has the potential to substantially impact nucleation and growth kinetics relative to the bulk. However, quantitative assessment of these differences in growth rates is complicated by challenges associated with discrimination of the two contributions (supersaturation and molecular mobility) in ensemble-averaged measurements. In the present study, "sandwich" materials were prepared, in which sparse populations of ritonavir single-crystalline seeds were pressed between two similar ASD films to assess bulk crystallization rates. These sandwich materials were compared and contrasted with analogously prepared "open-faced" samples, without the capping film, to assess the surface crystallization rates. Single-particle analysis by SHG microscopy time-series during in situ crystallization produced average growth rates of 3.8 µm/h for bulk columnar crystals with a particle-to-particle standard deviation of 0.9 µm/h. In addition, columnar crystal growth rates for surface particles were measured to be 1.3 µm/h and radiating crystal growth rates for surface particles were measured to be 1.0 µm/h, both with a particle-to-particle deviation of 0.4 µm/h. The observed appearance of radiating crystals upon surface seeding is attributed to reduced ritonavir solubility upon water adsorption at the interface, leading to higher defect densities in crystal growth. Despite substantial differences in crystal habit, correction of the surface growth rates by a factor of 4 from geometric effects resulted in relatively minor but statistically significant differences in the growth kinetics for the two local environments. These results are consistent, with viscosity being a relatively weak function of water absorption coupled with primarily diffusion-limited growth kinetics.


Subject(s)
Excipients/chemistry , Ritonavir/chemistry , Biological Availability , Chemistry, Pharmaceutical , Crystallization , Drug Liberation , Drug Stability , Drug Storage , Ritonavir/pharmacokinetics , Solubility
3.
J Pharm Sci ; 109(10): 3078-3085, 2020 10.
Article in English | MEDLINE | ID: mdl-32679216

ABSTRACT

In the pharmaceutical industry, amorphous solid dispersion can be utilized to enhance the solubility, hence bioavailability, of poorly solubility active pharmaceutical ingredients owing to the higher free energy of the amorphous state. Measuring the concentration, size and spatial distribution of crystalline API particles that may be present in amorphous solid dispersions (ASD) is critical to understanding product performance and developing improved formulations. In this study X-Ray Microscopy (XRM) was used to nondestructively measure these attributes in ASDs. Model tablets of amorphous fenofibrate in a copovidone matrix spiked with known concentrations of crystalline fenofibrate were examined by XRM to measure the concentration, size and distribution of crystalline particles in the tablets. Data collection and analysis conditions were evaluated and reported. XRM images showed contrast between the crystalline API and the amorphous matrix of the tablet. Image analysis using basic thresholding provided quantitative and distribution data of the crystallinity present. Crystals as small as 10 µm were detected and practical quantitation limits of 0.2% (w/w of total tablet) crystallinity were demonstrated. The aspects of manual data thresholding were tested for operator influence and threshold selection and found to be robust. This technique was demonstrated to provide quantitative measures of crystallinity below standard X-Ray Powder Diffraction (XRPD) techniques, provide three-dimensional information regarding size, shape and distribution of API crystals and can be performed nondestructively.


Subject(s)
Fenofibrate , Crystallization , Microscopy , Solubility , Tablets , X-Ray Diffraction , X-Rays
4.
Mol Pharm ; 17(3): 769-776, 2020 03 02.
Article in English | MEDLINE | ID: mdl-31769985

ABSTRACT

Single-particle tracking of crystal growth performed in situ enables substantial improvements in the signal-to-noise ratio (SNR) for recovered crystal nucleation and growth rates by nonlinear optical microscopy. Second harmonic generation (SHG) is exquisitely sensitive to noncentrosymmetric crystals, including those produced by many homochiral active pharmaceutical ingredients (APIs). Accelerated stability testing at elevated temperatures and relative humidity informs design of pharmaceutical formulations. In the present work, we demonstrate reduction in the Poisson noise associated with the finite number of particles present in a given field of view through continuous monitoring during stability testing. Single-particle tracking enables recovery of crystal growth rates of individual crystallites and enables unambiguous direct detection of nucleation events. Collectively, these capabilities provide significant improvements in the signal-to-noise for nucleation and crystal growth measurements, corresponding to approximately an order of magnitude reduction in anticipated measurement time for recovery of kinetics parameters.


Subject(s)
Drug Compounding/methods , Drug Design , Hexoses/chemistry , Pyrrolidines/chemistry , Ritonavir/chemistry , Silicon Dioxide/chemistry , Vinyl Compounds/chemistry , Colloids , Crystallization , Drug Stability , Humidity , Kinetics , Second Harmonic Generation Microscopy/methods , Signal-To-Noise Ratio , Solubility , Temperature , Water/chemistry
6.
Anal Chem ; 90(7): 4406-4413, 2018 04 03.
Article in English | MEDLINE | ID: mdl-29505717

ABSTRACT

The low limits of detection afforded by second harmonic generation (SHG) microscopy coupled with image analysis algorithms enabled quantitative modeling of the temperature-dependent crystallization of active pharmaceutical ingredients (APIs) within amorphous solid dispersions (ASDs). ASDs, in which an API is maintained in an amorphous state within a polymer matrix, are finding increasing use to address solubility limitations of small-molecule APIs. Extensive stability testing is typically performed for ASD characterization, the time frame for which is often dictated by the earliest detectable onset of crystal formation. Here a study of accelerated stability testing on ritonavir, a human immunodeficiency virus (HIV) protease inhibitor, has been conducted. Under the condition for accelerated stability testing at 50 °C/75%RH and 40 °C/75%RH, ritonavir crystallization kinetics from amorphous solid dispersions were monitored by SHG microscopy. SHG microscopy coupled by image analysis yielded limits of detection for ritonavir crystals as low as 10 ppm, which is about 2 orders of magnitude lower than other methods currently available for crystallinity detection in ASDs. The four decade dynamic range of SHG microscopy enabled quantitative modeling with an established (JMAK) kinetic model. From the SHG images, nucleation and crystal growth rates were independently determined.

SELECTION OF CITATIONS
SEARCH DETAIL
...